BioNTech (NASDAQ:BNTX) Upgraded by Evercore ISI to Outperform Rating

BioNTech (NASDAQ:BNTX) was upgraded by equities research analysts at Evercore ISI from an “in-line” rating to an “outperform” rating in a research note issued on Tuesday, MarketBeat reports. The firm presently has a $125.00 price objective on the stock, up from their previous price objective of $110.00. Evercore ISI’s price target suggests a potential upside of 22.71% from the company’s current price.

Other analysts also recently issued reports about the company. TD Cowen cut their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. Bank of America boosted their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating for the company in a research note on Monday, November 4th. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, UBS Group raised their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $138.79.

BioNTech Trading Up 2.2 %

NASDAQ BNTX opened at $101.87 on Tuesday. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $113.57 and its 200-day moving average price is $97.36. The stock has a market cap of $24.42 billion, a P/E ratio of -48.51 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue was up 38.9% compared to the same quarter last year. During the same period last year, the business earned $0.73 EPS. As a group, equities analysts forecast that BioNTech will post -3.68 EPS for the current fiscal year.

Institutional Trading of BioNTech

Several hedge funds have recently bought and sold shares of BNTX. Covestor Ltd lifted its position in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares in the last quarter. Planning Capital Management Corp lifted its holdings in BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares in the last quarter. Blue Trust Inc. boosted its position in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after purchasing an additional 238 shares during the period. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.